ProSomnus Announces Strong First Quarter 2024 Revenue Growth
GlobeNewswire
ProSomnus Records 28% Year-Over-Year Revenue Growth Accompanied by Continued Strong Customer Satisfaction
PLEASANTON,..
ProSomnus Records 28% Year-Over-Year Revenue Growth Accompanied by Continued Strong Customer Satisfaction
PLEASANTON,..
*If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately..
'Obamacare' Enrollment Surpasses Record , for 3rd Straight Year.
On Jan. 10, the Centers for Medicare and Medicaid Services..